Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$12,000.

  • Lineage Cell Therapeutics' Cash from Investing Activities fell 100.31% to -$12,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 5.98%. This contributed to the annual value of -$2.3 million for FY2024, which is 104.97% down from last year.
  • Lineage Cell Therapeutics' Cash from Investing Activities amounted to -$12,000 in Q3 2025, which was up 14.29% from -$14,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Cash from Investing Activities high stood at $19.2 million for Q2 2023, and its period low was -$40.9 million during Q3 2022.
  • Its 3-year average for Cash from Investing Activities is $4.2 million, with a median of $2.1 million in 2023.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Cash from Investing Activities crashed by 60,067.65% in 2022, and later surged by 33,634.78% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash from Investing Activities (Quarterly) stood at -$146,000 in 2021, then tumbled by 3,394.52% to -$5.1 million in 2022, then surged by 290.94% to $9.7 million in 2023, then plummeted by 72.95% to $2.6 million in 2024, then plummeted by 100.31% to -$12,000 in 2025.
  • Its Cash from Investing Activities stands at -$12,000 for Q3 2025, versus -$14,000 for Q2 2025 and $1.9 million for Q1 2025.